AFib ablation: Stop assuming success based on AFib type alone

Atrial fibrillation, the most common sustained arrhythmia, affects millions across Europe, presenting a complex management challenge for general practitioners and specialists alike. Its prevalence increases with age and the presence of cardiovascular comorbidities, including hypertension, heart failure, and obesity. While anticoagulation addresses stroke risk, rhythm control strategies aim to alleviate symptoms and prevent AFib-related cardiomyopathy. Antiarrhythmic drugs (AADs) are a first-line option, but their efficacy is limited by side effects and often modest success rates in maintaining sinus rhythm. Catheter ablation emerged as a more aggressive, but potentially more effective, rhythm control strategy for selected patients.

The procedure involves creating lesions in the left atrium, typically around the pulmonary veins, to isolate arrhythmogenic foci and prevent their propagation. Early techniques focused on pulmonary vein isolation (PVI), which remains the cornerstone of most ablation strategies. Subsequent refinements have explored additional lesion sets, such as posterior wall isolation, linear lesions, or targeting complex fractionated atrial electrograms (CFAE), particularly for persistent forms of AFib. The goal is to eliminate triggers and modify the atrial substrate that sustains the arrhythmia. The success of these interventions, however, varies considerably depending on patient characteristics and the type of AFib.

Defining the Ideal Candidate

Patients with paroxysmal atrial fibrillation (AFib episodes terminating spontaneously within seven days) consistently demonstrate the highest success rates with catheter ablation. Multiple registries and randomised controlled trials have shown that PVI alone can achieve freedom from AFib in 70-80% of these patients after a single procedure, often requiring a touch-up procedure to reach 85-90% success at one year. These patients typically have less atrial remodelling, smaller left atrial volumes, and fewer underlying structural heart abnormalities, making their AFib primarily driven by pulmonary vein triggers. The Oxford Handbook of Cardiology provides a concise overview of these patient selection criteria.

But the picture changes significantly for patients with persistent AFib (AFib lasting more than seven days) and long-standing persistent AFib (AFib lasting more than one year). For these groups, the atrial substrate is often more extensively remodelled, with greater fibrosis and electrical heterogeneity, making PVI alone less effective. Initial success rates for persistent AFib often hover around 50-60% after a single procedure, and for long-standing persistent AFib, they can drop to 30-50%. These lower rates frequently necessitate multiple procedures and more extensive ablation strategies beyond PVI, which carry their own increased risks.

The Impact of Atrial Remodelling and Fibrosis

Left atrial size is a well-established predictor of ablation success. Patients with a left atrial diameter (LAD) of less than 4.5 cm generally fare better than those with significant left atrial enlargement (LAD > 5.0 cm). The presence and extent of left atrial fibrosis, often assessed non-invasively by cardiac magnetic resonance imaging (CMR), also strongly correlate with outcomes. Patients with minimal or no atrial fibrosis (less than 10% of the left atrial wall) have significantly higher rates of freedom from AFib compared to those with extensive fibrosis (greater than 20-25%). This is because fibrotic tissue acts as a substrate for re-entry circuits, making it resistant to ablation and more prone to arrhythmia recurrence.

Age also plays a role, though less directly than atrial remodelling. Younger patients, typically under 65 years, tend to have less advanced atrial disease and fewer comorbidities, contributing to better ablation outcomes. Older patients, while still benefiting, may have a higher burden of comorbidities and more extensive atrial remodelling, which can limit the durability of rhythm control. However, age alone should not be an absolute contraindication, particularly if the patient is otherwise healthy and symptomatic.

Comorbidities and Procedural Risk

The presence of comorbidities significantly influences both the efficacy and safety of catheter ablation. Hypertension, diabetes, obesity, and obstructive sleep apnoea are all independent risk factors for AFib recurrence post-ablation. Aggressive management of these conditions, including weight loss for obese patients and continuous positive airway pressure (CPAP) for sleep apnoea, can improve ablation success rates. For example, studies have shown that weight loss of >10% in obese AFib patients can reduce AFib recurrence by 30-40%, even before ablation. The overall burden of comorbidities, often quantified by scores like the CHA2DS2-VASc score, also correlates inversely with long-term success.

Procedural risks, while generally low, are not negligible. Major complications, including cardiac tamponade, stroke, oesophageal fistula, and phrenic nerve injury, occur in approximately 1-3% of procedures. Minor complications, such as vascular access site issues or pericardial effusion, are more common. The risk-benefit ratio must be carefully weighed, especially in patients with multiple comorbidities or advanced heart disease, where the potential for durable rhythm control may be lower and the procedural risk higher. For instance, patients with severe left ventricular dysfunction (ejection fraction <35%) face higher risks and often derive less symptomatic benefit from ablation.

The Role of Early Intervention

Emerging evidence suggests that earlier intervention with catheter ablation, particularly in patients with paroxysmal AFib, may lead to better long-term outcomes and potentially prevent atrial remodelling. The EAST-AFNET 4 trial, for example, demonstrated that early rhythm control, including ablation or AADs, improved cardiovascular outcomes compared to usual care in patients with recently diagnosed AFib. While that trial did not exclusively focus on ablation, it underscored the importance of early rhythm management. For patients with symptomatic paroxysmal AFib who have failed or are intolerant to one AAD, catheter ablation is a Class I recommendation in current European guidelines.

Still, the decision to proceed with ablation requires a comprehensive assessment of patient symptoms, AFib type, left atrial characteristics, and comorbidity burden. A shared decision-making approach, where patients understand the potential benefits, risks, and alternatives, is paramount. For some, particularly those with minimal symptoms or extensive atrial remodelling, a rate control strategy may be more appropriate and safer. The long-term impact of ablation on hard endpoints like stroke or mortality, beyond symptom relief and rhythm maintenance, remains an area of ongoing research, especially in populations beyond those with heart failure.

Where it Falls Short

The primary limitation of many ablation studies is their focus on freedom from AFib as the primary endpoint, often defined as no AFib episodes longer than 30 seconds after a 3-month blanking period. This definition does not always translate directly to improved quality of life or a reduction in hard clinical events. Many patients may experience a reduction in AFib burden rather than complete elimination, which can still be clinically meaningful but is not captured by a binary endpoint. The reliance on intermittent ECG monitoring also risks underestimating AFib recurrence, particularly for asymptomatic episodes. Continuous monitoring with devices like the AliveCor KardiaMobile 6L Personal ECG can provide a more accurate picture of AFib burden.

Another caveat is the generalisability of trial results. Many pivotal trials enrolled highly selected patient populations, often younger, with paroxysmal AFib and fewer comorbidities, which may not reflect the broader patient population seen in routine clinical practice. The learning curve for operators and the variability in ablation techniques across centres also contribute to differences in reported success rates. Furthermore, the long-term efficacy beyond five years remains less well-defined, with some studies showing a gradual decline in freedom from AFib over time, even in initially successful patients.